A joint research team from Chonnam National University and Inje University identified the molecular mechanism by which high blood pressure worsens osteoarthritis. The brain hormone vasopressin bound to receptors in damaged cartilage, promoting cartilage breakdown. The team plans
10 days ago
GC Biopharma presented research findings on its internally developed mRNA-LNP platform at domestic and international conferences. By applying AI-based codon optimization technology to proprietary UTR sequences and a poly(A) structure, the company increased protein translation eff
10 days ago
Samsung Bioepis has signed a global licensing, development and commercialization agreement with Israel-based Teva for up to six biosimilar candidates. The agreement includes two confirmed candidates, SB41 and SB44. Samsung Bioepis will handle development and manufacturing, while
10 days ago
Dr. Oregonin has completed U.S. Food and Drug Administration (FDA) product registration for Oltis Dental X, a toothpaste-type quasi-drug based on alder native to Gangwon Province. The product suppressed expression of the periodontal inflammation factor TNF-α by up to 146 times co
10 days ago
The Ministry of Food and Drug Safety said four amendments to laws under its jurisdiction, including the Pharmaceutical Affairs Act, passed the National Assembly plenary session. An amendment to the Pharmaceutical Affairs Act will formalize patient support programs through which p
10 days ago
Samo Pharmaceutical held 39,020,249 shares and other securities in Aminologics. Samo Pharmaceutical acquired 4,779,854 shares through the exercise of a put option on the fourth convertible bond issue. Samo Pharmaceutical used 4.68983 billion won in available funds for the acquisi
10 days ago
Eli Lilly said that in a phase 2 trial in people with obesity, the group receiving the highest dose of Zepbound combined with eloralintide recorded an average weight loss of 23% (about 54 pounds) over 48 weeks. The high-dose Zepbound monotherapy group lost 15%, while the eloralin
10 days ago
The U.S. Department of Health and Human Services (HHS) unveiled the “Surpass” program, which shifts clinical development from sequential trials to a continuous-learning system. Over five years, HHS will recruit teams with innovative ideas and provide government funding and suppor
10 days ago
Japan’s Taiho Pharmaceutical said its oral combination therapy of azacitidine and cedazuridine met the primary endpoint in a Phase 3 trial. The combination therapy produced azacitidine exposure comparable to subcutaneous administration in patients with myelodysplastic syndromes a
10 days ago
Eli Lilly said its oral GLP-1 drug Foundayo reduced the risk of cardiovascular death by 53% compared with insulin glargine. In a phase 3 trial, Foundayo also reduced the risk of death from any cause by 57%. Eli Lilly will seek approval for a type 2 diabetes indication based on th
10 days ago
